Angiomyofibroblastoma of Vulva

Emel Kurtoglu¹, Rabia Kaya², Nevin Topak³

ABSTRACT

Angiomyofibroblastoma is a rare, benign, well-circumscribed neoplasm predominantly occurring in the pelviperineal region of middle-aged women. The tumour cells are round-to-spindle shaped concentrated around vessels. They almost have immunoreactivity for desmin and vimentin, consistently positive for estrogen and progesterone receptors, occasionally positive for CD 34. The complete surgical excision of the tumour is necessary. It is important to distinguish this tumour from especially aggressive angiomyxoma to avoid inadequate treatment. Here, we report a case of vulvar angiomyofibroblastoma in a 46-year-old postmenopausal woman whose findings were differentiating from others. Histologically, the tumour involved fibroadipose tissue and immunoreactivity for desmin and actin was negative.

Key words: Angiomyofibroblastoma, vulva, postmenopause

INTRODUCTION

Angiomyofibroblastoma (AMFB) is a rare, well-circumscribed mesenchymal neoplasm, usually arising in the pelviperineal region, especially the vulva and apparently composed of stromal cells distinctive to this anatomic region (1). It was first described by Fletcher et al. in 1992 as a new entity (2). This tumour arises predominantly in females, principally in adults between menarche and menopause (2-6). Ten percent (10%) of patients are postmenopausal and rare cases occur in males which are defined as male angiomyofibroblastoma-like tumour (2,6). Most cases present as a slowly enlarging, painless, circumscribed mass and are often misdiagnosed as a Bartholin’s gland cyst and hydrocele of the canal of Nuck (7,8). These lesions are well-circumscribed but not encapsulated with a thin-pink cut surface and soft consistency (1). Histologically, these tumours show varying cellularity with prominent vessels. The vessels are mostly small, thin-walled, ectatic and are set in an abundant loose, oedematous stroma. The tumour cells are round-to-spindle shaped with eosinophilic cytoplasm and are often misdiagnosed as a Bartholin’s gland cyst and hydrocele of the canal of Nuck. Mitosis are rare (1). The majority of cases have immunoreactivity for desmin and vimentin. They are consistently positive for estrogen and progesterone receptors, occasionally positive for CD 34 and negative for S100 protein, keratin and fast myosin (9,10). The recommended treatment is complete surgical excision of the tumour. Although these tumours doesn’t tend to recur locally, follow-up examination is necessary (9).

Histopathological differential diagnosis include cellular angiomyofibroma, aggressive angiomyxoma, myxoid li-
Angiomyofibroblastoma of vulva

Figure 1. Capillary structure and scattered adipocytes (H/E X40)

Figure 2. Vascular and capillary-like structure in a loose matrix (H/E X20)

Figure 3. Strong and diffuse vimentin positivity (Vimentin x40)

Figure 4. Endothelial cells are positive for CD 34 (CD 34x40)

CASE

A 46-year-old postmenopausal woman presented with a painful, slow-growing vulvar mass. The patient gave a history of small nodular mass in her vulvar region starting nine years before, which had grown slowly and became painful during the last two months. On physical examination, a soft, mobile and painful mass, measuring almost 4x3x2 cm, was seen in the left labia majora. The patient had no medical and family history of note except being a hepatitis B carrier. There was no abnormality on vaginal examination, pelvic ultrasonography imaging and laboratory examination. A simple tumour excision was performed to the patient. Macroscopically, the resected tumour had a brownish soft appearance, measuring 3x4x3 cm. Microscopically, fibroadipose tissue (Figure 1), having hypo-and hypercellular areas with capillary blood vessels and mast cells were seen (Figure 2). There was no atypical mitosis. In immunohistochemistry, tumour cells were strongly positive for vimentin (Figure 3), CD 34 (Figure 4), estrogen and progesterone receptors, focal positive for S-100 protein and negative for desmin, actin and pancytokeratin. The index of Ki 67 in cellular areas was 4%.

DISCUSSION

AMFB is a rare and usually benign mesenchymal tumour that predominantly involves premenopausal women, but we report a 46-year-old postmenopausal patient.
who presented with a vulvar AMFB. The tumour has a predilection for lower genital tract of women and men, but unusual regions of female and male can be involved like fallopian tube, perianal region, retroperitoneal and male inguinal region (8,10,12,14). Most cases measure less than 5 cm in maximum diameter, as in the our case, although rare examples measuring up to 10 cm have been recognized (1). Nagai K et al. reported a huge pedunculated AMFB of the vulva at a 48-year-old woman, which was 23 cm in diameter and weighed 4534 g (4). There are only a few case reports of huge AMFB in the literature (9,16). Angiomyofibroblastoma has characteristic histomorphologic features and shows myofibroblastic differentiation. The tumours are generally well demarcated by a thin fibrous pseudocapsule and have alternating hypo- and hypercellular areas with abundant thin-walled blood vessels which were surrounded by stromal cells within an oedematous to collagenous matrix (9).

Ten percent (10%) of cases have a variably prominent well differentiated adipocytic component in postmenopausal patients as in our patient (1). Immunoreactivity for desmin and vimentin is detected in the majority of tumour cells, which are consistently positive for estrogen and progesterone receptors (1,9). But in postmenopausal women, desmin staining may be reduced and absent, and also in pregnancy, the tumour cells can be negative for estrogen and progesterone receptors (1,13). In our case, immunoreactivity for desmin was negative, too. As some cases show morphologic overlap with cellular angiofibroma and aggressive angiomyxoma, it is too important to recognize AMFB and distinguish it from other overlapping tumours, especially aggressive angiomyxoma to avoid inadequate treatment. AMFB is entirely benign, does not recur locally, even after marginal local excision although aggressive angiomyxoma has a local recurrence rate of approximately 30% and has a rare metastatic potential (1,16,17). We have had no involvements that might raise the question of bias in the work reported or in the conclusions, implications or opinions stated.

REFERENCES